Key result
Physician-modified endografts for TEVAR left subclavian management require rigorous documentation under EU MDR regulations.
Why the study?
Management of the left subclavian artery (LSA) during thoracic endovascular aortic repair (TEVAR) requires integrating multiple clinical and procedural factors and may raise medico-legal and regulatory concerns, particularly when involving intentional LSA coverage, revascularization, or physician-modified endografts (PMEGs).
Clarifies the medico-legal and European regulatory considerations (Regulation (EU) 2017/745) surrounding off-label device use and physician-modified endografts for left subclavian artery management during TEVAR.
Answers are grounded in this paper and cite their sources.
Raises awareness of medico-legal risks with LSA coverage or PMEGs in TEVAR; leaves open standardized protocols under EU MDR.
Management of the left subclavian artery (LSA) during thoracic endovascular aortic repair (TEVAR) requires integration of anatomical, neurologic, procedural, and patient-related factors and may raise medico-legal concerns, particularly with intentional LSA coverage, revascularization, or physician-modified endografts (PMEGs). This article examines the main medico-legal and regulatory issues related to LSA management, including device instructions for use (IFU), off-label use, physician modification, professional competence, institutional governance, product liability, informed consent, and documentation. The European regulatory framework, particularly Regulation (EU) 2017/745, is considered alongside principles of professional liability and patient autonomy. Regulatory compliance should be distinguished from the clinical standard of care, as neither treatment within the IFU nor off-label use alone determines the appropriateness of a clinical decision. In innovative strategies, informed consent should address uncertainties, benefits, alternatives, and risks, while medical records should document the rationale for treatment. A patient-specific, evidence-informed, and well-documented approach is essential to balance innovation, patient safety, and medico-legal responsibility.
No takes yet. Share an insight, caveat, or question.
Sirignano et al. (2026) conducted a review in Thoracic aortic disease requiring thoracic endovascular aortic repair (TEVAR) with left subclavian artery (LSA) management. Left subclavian artery management during TEVAR (intentional coverage, revascularization, or physician-modified endografts) was evaluated. Left subclavian artery management during TEVAR using physician-modified endografts requires rigorous informed consent and clinical documentation under EU Regulation 2017/745.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: